Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -445.98% is 25% above its 5-year average of -597.48%, near the high end of its 5-year range (-1207.72%–-389.84%).
7.07% above its 12-month average of -479.93%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -494.91%.
EBITDA MARGIN
-445.98%
EBITDA MARGIN AVG TTM
-479.93%
EBITDA MARGIN AVG 3Y
-521.46%
EBITDA MARGIN AVG 5Y
-597.48%
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+7.07%
CURRENT VS 3Y AVG
+14.47%
CURRENT VS 5Y AVG
+25.36%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Seer, Inc.
Market Cap
$121.78M
EBITDA Margin
-445.98%
TTM Avg
-479.93%
3Y Avg
-521.46%
5Y Avg
-597.48%
Market Cap
$121.37M
EBITDA Margin
-1691.15%
TTM Avg
-1668.02%
3Y Avg
-8474.77%
5Y Avg
-5696.48%
Market Cap
$119.56M
EBITDA Margin
-1142.44%
TTM Avg
-828.55%
3Y Avg
-828.55%
5Y Avg
-828.55%
Market Cap
$119.26M
EBITDA Margin
-29.32%
TTM Avg
-13.32%
3Y Avg
-6.17%
5Y Avg
-1.07%
Market Cap
$124.98M
EBITDA Margin
-944.37%
TTM Avg
-1132.38%
3Y Avg
-1244.49%
5Y Avg
-1244.49%
Market Cap
$117.31M
EBITDA Margin
-475.96%
TTM Avg
-475.96%
3Y Avg
-272.89%
5Y Avg
-272.89%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Seer, Inc. (SEER) | $121.78M | -445.98% | -479.93% | -521.46% | -597.48% |
| TuHURA Biosciences, Inc. (HURA)vs › | $121.95M | N/A | N/A | N/A | N/A |
| Cibus, Inc. (CBUS)vs › | $121.37M | -1691.15% | -1668.02% | -8474.77% | -5696.48% |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A | N/A | N/A | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.35M | N/A | N/A | N/A | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.56M | -1142.44% | -828.55% | -828.55% | -828.55% |
| BGM Group Ltd. (BGM)vs › | $119.26M | -29.32% | -13.32% | -6.17% | -1.07% |
| Tonix Pharmaceuticals Holding Corp. (TNXP)vs › | $124.98M | -944.37% | -1132.38% | -1244.49% | -1244.49% |
| LENZ Therapeutics, Inc. (LENZ)vs › | $117.31M | -475.96% | -475.96% | -272.89% | -272.89% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $126.64M | -1312.73% | -1312.73% | -1312.73% | -1312.73% |
Gross Margin
46.3%
EBITDA Margin
-446.0%
Operating Margin
-483.9%
Net Margin
-490.7%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -494.91% |
| 2026-03-31 | -581.26% |
| 2025-12-31 | -389.84% |
| 2025-09-30 | -450.77% |
| 2025-06-30 | -482.86% |
| 2025-03-31 | -461.59% |
| 2024-12-31 | -555.36% |
| 2024-09-30 | -577.19% |
| 2024-06-30 | -833.14% |
| 2024-03-31 | -772.93% |
| 2023-12-31 | -494.07% |
| 2023-09-30 | -584.98% |
| 2023-06-30 | -663.25% |
| 2023-03-31 | -644.93% |
| 2022-12-31 | -617.61% |
| 2022-09-30 | -606.90% |
| 2022-06-30 | -622.29% |
| 2022-03-31 | -691.76% |
| 2021-12-31 | -595.88% |
| 2021-09-30 | -828.02% |
| 2021-06-30 | -1207.72% |
| 2021-03-31 | -25832.26% |
| 2020-12-31 | -3740.18% |
| 2020-06-30 | -8659.15% |
| 2019-12-31 | -8948.28% |
